@alexaaronlab 6-8 week rebound stack: KLOW + extra KPV + extra BPC-157 + Reta + MT2
After 7 weeks off of peptides I am finally starting back up again. Here's my stack Protocol: KLOW: 2mg/day KPV(on top of KLOW): 0.3mg/day BPC-157(on top of KLOW):0.75mg/day Retatrutide: 2.5mg/wk MT2: short load phase then 0.15mg/wk On hand(only use if needed): Thymosin alpha 1 Glutathione NAD+ I am most likely going to introduce CJC/ipamorelin as well as MotsC soon. Main goal: after being abroad for 5 months, i need to recomp my physique, lose fat, lower inflammation, and fix my digestion. I'm in a rebound and recovery phase for the next 6-8 weeks.
A thoughtfully-disclosed rebound stack. Author uses KLOW as a baseline then adds extra KPV and BPC-157 on top, showing he understands the blend isn't titrated for any single compound. Reta at 2.5mg/wk is conservative for the recomp goal (Phase 2 dose range starts at 4mg). The active vs 'on hand' distinction (Ta-1, glutathione, NAD held in reserve) is more mature than most. Time-bounded 6-8 week framing tied to a specific 5-month-abroad rebound is the kind of goal-shaped protocol most stacks lack. Retatrutide sourcing applies.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | 75 | C | 10% | GHK-Cu (in KLOW) and glutathione (on hand) touch antioxidant and aging mechanisms; not the headline goal but the stack indirectly supports healthspan during a recovery phase. |
| Cognition | — | Not targeted | — | No ingredient with a primary cognitive mechanism. |
| Sleep & recovery | 80 | B- | 30% | KLOW (BPC-157 + TB-500 + GHK-Cu + KPV) plus extra BPC-157 and KPV on top is one of the better recovery-peptide setups in the corpus, dosed at sensible research-vendor levels. |
| Energy & metabolism | 78 | C+ | 15% | Retatrutide at 2.5mg/wk covers the metabolic axis; conservative dose is consistent with the rebound framing rather than aggressive weight loss. |
| Body recomposition | 82 | B- | 45% | Reta + KLOW recovery support during a post-deficit rebound is a sensible composition. Held off the higher B range by retatrutide sourcing concerns and the absence of any training detail in the post. |
Ingredients (8)
KLOW blend
- Dose
- 2mg/day · daily
- Mechanism
- Community-recognized peptide blend containing BPC-157, TB-500, GHK-Cu, and KPV in a fixed ratio. Marketed for recovery and tissue repair.
- Take
- KLOW is a community-recognized blend (BPC-157 + TB-500 + GHK-Cu + KPV) so the composition is a known quantity. 2mg/day total is in the typical enthusiast range. Author treats it as a baseline rather than a complete protocol, then adds individual KPV and BPC-157 on top for the components he wants more of. That's actually thoughtful, since KLOW's fixed ratio isn't titrated for any specific compound's optimal dose.
KPV (on top of KLOW)
KPV (on top of KLOW) on peptidelist.org ↗
- Dose
- 0.3mg/day on top of KLOW · daily
- Mechanism
- C-terminal tripeptide of α-MSH; preclinical evidence for anti-inflammatory effects, particularly in murine models of inflammatory bowel disease.
- Take
- Additional KPV beyond what's already in 2mg KLOW. KPV's strongest preclinical case is anti-inflammatory effects in IBD models, which fits the author's 'fix digestion' goal. 0.3mg/day on top is reasonable; total daily KPV is whatever's in 2mg KLOW plus this 0.3mg. The extra dose makes sense if gut inflammation is a real target.
BPC-157 (on top of KLOW)
BPC-157 (on top of KLOW) on peptidelist.org ↗
- Dose
- 0.75mg/day on top of KLOW · daily
- Mechanism
- Pentadecapeptide derived from a gastric protein; preclinical evidence for angiogenesis, fibroblast migration, and growth factor signaling. No published human RCTs.
- Take
- Additional BPC-157 beyond what's in the KLOW blend. 0.75mg/day on top brings total BPC-157 well into the standard 200-500mcg/day enthusiast range, biased toward the high end. Reasonable for a rebound phase emphasizing tissue repair and gut healing.
Retatrutide
Retatrutide on peptidelist.org ↗
- Dose
- 2.5mg/wk · weekly
- Mechanism
- GLP-1 / GIP / glucagon triple-receptor agonist. Eli Lilly trial drug; Phase 2 data exceeded tirzepatide and semaglutide on bodyweight outcomes.
- Take
- Conservative dose. Phase 2 trial titration started at 2mg/wk and went up to 12mg/wk; 2.5mg/wk is at the lower end of the trial range, consistent with the 'rebound recomp' framing rather than aggressive weight loss. Standard retatrutide caveat applies: Phase 3 trial-stage drug, no legitimate civilian supply chain, anything from a research-peptide vendor is gray-market or unverifiable counterfeit.
Melanotan 2
Melanotan 2 on peptidelist.org ↗
- Dose
- short load phase, then 0.15mg/wk maintenance · weekly maintenance
- Mechanism
- α-MSH analog activating melanocortin receptors: MC1R for melanogenesis (skin pigmentation independent of UV), MC4R for appetite suppression and sexual function. Synthetic, not FDA-approved.
- Take
- Standard MT2 protocol pattern: load to establish pigmentation, then drop to maintenance. 0.15mg/wk maintenance is on the low end of typical maintenance dosing (most users run 0.25-0.5mg/wk). Probably a cosmetic-tan goal rather than appetite suppression at this dose. Standard MT2 concerns apply: existing nevi surveillance, occasional priapism, blood-pressure changes. Not FDA-approved anywhere.
Thymosin Alpha-1 (on hand)
Thymosin Alpha-1 (on hand) on peptidelist.org ↗
- Dose
- on hand, use if needed · reactive
- Mechanism
- Synthetic version of a thymic-derived 28-amino-acid peptide. Immunomodulator with FDA orphan-drug status for some indications and EU approval for chronic hepatitis B. Modulates T-cell maturation and innate immune function.
- Take
- Held in reserve rather than scheduled. Reasonable approach for a peptide that's most useful during immune challenge or illness. Subcutaneous use at 1.6mg twice weekly is the published HBV protocol; for ad-hoc use during illness, similar dosing applies. Author hasn't specified what triggers reaching for it.
Glutathione (on hand)
Glutathione (on hand) on peptidelist.org ↗
- Dose
- on hand, use if needed · reactive
- Mechanism
- Tripeptide (glutamate-cysteine-glycine) and the body's primary endogenous intracellular antioxidant. Substrate for glutathione peroxidase and key in phase II liver detoxification.
- Take
- On-hand antioxidant support. Effective form and route matter: oral reduced glutathione has poor bioavailability, NAC at 600-1200mg is the supplement with the better evidence base for raising endogenous glutathione, and IV glutathione is the route with most clinical use. Author doesn't specify form.
NAD+ (on hand)
NAD+ (on hand) on peptidelist.org ↗
- Dose
- on hand, use if needed · reactive
- Mechanism
- NAD+ is a coenzyme central to mitochondrial energy production and sirtuin/PARP enzyme activity. Supplemented as IV NAD+, oral NMN/NR precursors, or subcutaneous NAD+.
- Take
- Held in reserve. As always with NAD, the form matters: IV NAD ($300-1500/session, weak evidence) vs oral NMN/NR precursors at 500-1000mg/day (lower cost, weaker biomarker evidence). For an on-hand reactive use case, oral precursors make more sense than scheduling IV sessions.
Risks & interactions
- Retatrutide has no legitimate civilian supply chainhigh
Phase 3 trial-stage drug, not FDA-approved. Anything sold as 'retatrutide' on the research-peptide market is gray-market trial diversion or unverifiable counterfeit synthesis. Counterfeit GLP-1-class drugs have been documented with off-target compounds. The conservative 2.5mg/wk dose softens the impact but doesn't change the sourcing math.
- Eight simultaneous compounds (active + on-hand) defeat n=1 attributionmedium
Five active compounds plus three on-hand reactive ones means subjective changes during the 6-8 week cycle can't be cleanly attributed to any single ingredient. Author plans to add CJC/Ipa and MOTS-c 'soon' on top, which compounds the attribution problem. The stated 'rebound' framing is reasonable but tracking will yield more vibes than data.
- Goals are stated but not measuredmedium
Recomp, fat loss, lower inflammation, fix digestion are real goals, but none has a stated outcome measure. Without a baseline DEXA/body-comp, a CRP, or a gut symptom diary, post-cycle assessment will be subjective. The stack is goal-shaped enough to deserve measurement.
- Melanotan 2 nevi surveillancemedium
MC1R activation accelerates melanogenesis in existing moles. Users with significant nevi history, family melanoma history, or atypical-mole syndrome shouldn't freelance MT2. Maintenance use should be paired with annual dermatology surveillance.
- KLOW + on-top dosing requires vendor consistencylow
Adding extra KPV and BPC-157 on top of a KLOW baseline assumes the per-component dose in the KLOW vial is what the vendor says it is. Reputable peptide vendors with COAs reduce the variance; the stacking-on-top strategy works less well if the underlying blend's composition drifts batch to batch.
Author has a goal-shaped stack with a specific time horizon (6-8 weeks) and named outcomes (recomp, fat loss, lower inflammation, fix digestion). Pairing those goals with measurable endpoints turns the cycle from 'I felt better' into 'body weight dropped X with lean mass preserved, stool form normalized, CRP went from Y to Z.' Without measures, the author won't know which compounds did the work or whether the planned 'soon to add' CJC/Ipa and MOTS-c are warranted. The stack is mature enough to deserve real outcome tracking.
Estimated cost
KLOW blend ~$80-150/mo at 2mg/day from research-peptide vendors. Extra KPV ~$30-50/mo, extra BPC-157 ~$30-50/mo. Retatrutide $300+ if sourceable (with the central caveat that it isn't legitimately available). MT2 ~$30-50/mo at maintenance dose. On-hand Ta-1, glutathione, NAD aren't running cost unless used.